Could carbon monoxide and bilirubin be friends as well as foes of the body?

Abstract

Endogenous carbon monoxide (CO) production was first described 60 years ago. CO is a by-product of the metabolism of haeme to biliverdin. This, in turn, becomes bilirubin. During the past 15 years epidemiological studies and animal experiments have identified bilirubin as a molecule at the crossroads of the protection of the body against reactive oxygen species (ROS). The studies have focused on bilirubin as a biomarker of arterial disease. Recently the potential of CO as a therapeutic agent has been explored. This review assesses the current state of evidence and sets the data in the context of whether CO is an endogenous signalling molecule, a marker of vascular disease and, whether, together with bilirubin, CO could be a potential therapeutic agent.

Key Words::

• Carbon monoxide
• bilirubin
• reactive oxygen species
• vascular disease
• CO-RMs
• signalling

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.